AISF position paper on nonalcoholic fatty liver disease (NAFLD): Updates and future directions by Lonardo, Amedeo et al.
AISF position paper on nonalcoholic fatty liver disease (NAFLD): Updates and future directions _ The Italian Association for the Study of the Liver (AISF)

ABSTRACT. This review summarizes our current understanding of nonalcoholic fatty liver disease (NAFLD), a multifactorial systemic disease resulting from a complex interaction between a specific genetic background and multiple environmental/metabolic “hits”. The role of gut microbiota, lipotoxicity, inflammation and their molecular pathways is reviewed indepth. We also discuss the epidemiology and natural history of NAFLD by pinpointing the remarkably high prevalence of NAFLD worldwide and its inherent systemic complications: hepatic (steatohepatitis, advanced fibrosis and cirrhosis), cardio-metabolic (cardiovascular disease, cardiomyopathy, arrhythmias and type 2 diabetes) and neoplastic (primary liver cancers and extra-hepatic cancers). Moreover, we critically report on the diagnostic role of non-invasive biomarkers, imaging techniques and liver biopsy, which remains the reference standard for diagnosing the disease, but cannot be proposed to all patients with suspected NAFLD. Finally, the management of NAFLD is also reviewed, by highlighting the lifestyle changes and the pharmacological options, with a focus on the innovative drugs. We conclude that the results of ongoing studies are eagerly expected to lead to introduce into the clinical arena new diagnostic and prognostic biomarkers, prevention and surveillance strategies as well as to new drugs for a tailored approach to the management of NAFLD in the individual patient.
1.	Introduction





PathogenesisNAFLD is a multi-factorial disease resulting from a complexinteraction of environmental “hits” and a genetic background(Fig. 1). A high-calorie diet, often coupled with a sedentary behav-ior, contribute to the development of NAFLD, both directly and viaweight gain. Dietary excess of saturated fats and refined carbohy-drates has been associated with NAFLD and a high fructose intakemay increase the risk of NASH [16,17]. Development and progres-sion of NAFLD are strongly associated with insulin resistance (IR)and metabolic syndrome (MetS) components, particularly abdom-inal obesity and T2DM [18]. The most common cause of NAFLDis an altered whole-body energetic homeostasis, due to caloricintake exceeding caloric expenditure, with consequent spilloverof extra-energy in the form of non-esterified fatty acids (NEFA)from visceral adipose tissue into ectopic fat depots, such as theliver, skeletal muscles and pancreas [19]. NAFLD will invariablydevelop when the rate of hepatic triglyceride flowing to the livervia the bloodstream or synthesized within the liver exceeds therate of hepatic triglyceride oxidation and VLDL secretion into thebloodstream [19]. Approximately 60% of hepatic lipids derives fromincreased peripheral lipolysis of triglycerides (due to adipose tis-sue IR and failure to adequately suppress peripheral triglyceridelipolysis), while dietary fats and sugars contribute approximately35–40% [20]. The liver itself may also contribute to steatogenesis bysynthesizing triglycerides from dietary carbohydrates through denovo lipogenesis. The contribution of de novo lipogenesis to liverfat content is less than 5% in healthy subjects and may increase toapproximately 25% in NAFLD patients [20]. Intra-hepatocytic accu-mulation of diacylglycerol intermediates impairs hepatic insulinsignaling and fuels gluconeogenesis, so promoting hyperglycemiaand predisposing to the development of T2DM [21]. Increasedamounts of circulating and intracellular NEFAs are also associ-ated with an increase in nuclear factor kappa-B (NF- _B), eventuallyleading to the expanded and dysfunctional adipose tissue overpro-ducing multiple pro-inflammatory cytokines and under-producinganti-inflammatory adipokines, such as adiponectin which, collec-tively, may further dictate NAFLD progression [22,23].

2.2.	Lipotoxicity and inflammation
As shown in Fig. 1, NASH progression results from numerousevents originating within the liver and in distal organs, includingthe visceral adipose tissue and the gastrointestinal tract [24]. Fat-induced damage to the hepatocytes (lipotoxicity), is more linkedto the abundance of specific toxic compounds, such as NEFAs andceramides, than to the total amount of stored fat [25]. Evidencefrom genetic studies, on the other hand, suggests that the amountof fat accumulation is important [26]. Toxic lipids can determinecell injury through a variety of mechanisms, including increasedoxidative stress and mitochondrial dysfunction. Saturated fattyacids are increased in NASH [24,25] and induce inflammation andhepatocyte apoptosis by activating Jun N-terminal kinase (JNK) and mitochondrial pathways [27]. Free cholesterol is a prominentmechanism for NASH development and progression. Interestingly,necroptosis has been recently described as a cell death mechanismpotentially involved in lipotoxicity, which is morphologically com-parable to necrosis, though characterized by definite biochemicalpathways [28].Endoplasmic reticulum (ER) stress also takes part in NASHpathogenesis, as the result of the induction of the unfolded proteinresponse, which is an adaptive mechanism potentially trigger-ing apoptosis. JNK, an activator of inflammation and apoptosisimplicated in NAFLD progression, is one of the major media-tors of ER stress [29]. Hypoxia perturbs lipid homeostasis andinsulin signaling pathways. Moreover, reduced oxygen availabil-ity induces secretion of pro-inflammatory cytokines [30]. Theseadverse effects are mediated by two hypoxia-inducible transcrip-tion factors (HIF-1 _ and HIF-2 _), which regulate cellular responseto oxygen deficiency and can be activated by additional stimuliinvolved in NASH, including oxidative stress or inflammatory sig-nals [30].Chronic inflammation is a key factor in NASH pathogenesis.Kupffer cell activation occurs at an early stage, and precedes therecruitment of other cells. Attention has been paid to the differentphenotypes of Kupffer cells, i.e., M1 and M2, considered primar-ily immuno-regulatory [31]. Hepatocyte death is a strong triggerof inflammation and fibrosis, through signaling pathways thatinclude tumor necrosis factor (TNF)-related apoptosis-inducingligand receptor, Fas and TNF receptor, and promote the expressionof several cytokines and chemokines. Differentiation toward a pro-inflammatory ‘M1 phenotype’ is driven by pathogen-associatedmolecular patterns (PAMPs) and damage-associated molecularpatterns (DAMPs) interacting with toll-like receptors (TLR), andinduces expression of pro-inflammatory factors, such as interleukin(IL)-1 _, IL-12, TNF- _, and chemokines CCL2 and CCL5 [32]. Remark-ably, chemokines such as CCL2 and CCL5 may induce hepaticstellate cell activation, triggering fibrogenesis. Besides resident andinfiltrating macrophages, the role of other inflammatory cells, suchas neutrophils, lymphocytes, NK cells and dendritic cells is activelybeing evaluated [24]. 
TLRs recognize endogenous danger signals, such as DAMPs orPAMPs [32]. TLR-induced pathways play a central role in the acti-vation of hepatic cells, primarily Kupffer cells, but also hepatocytesand stellate cells. TLR2 interacts with multiple PAMPs, which areincreased in NAFLD, and its inhibition prevents hepatic/systemicIR in high-fat diet–fed mice [32]. TLR9 is activated by unmethy-lated DNA, typically expressed in viruses and bacteria but rare inmammalian cells. TLR9 downstream signaling involves IL-1, andis associated with NASH severity and fibrosis. The pivotal role ofTLR4 in the pathogenesis of NASH has been shown in TLR4-deficientmice that display lower levels of inflammation and fibrosis. TLR4is primarily activated by bacterial lipopolysaccharide, triggeringexpression of cytokines and chemokines (e.g., TNF- _, IL-1 _, IL-6and IL-12) [33]. Reactive oxygen species are also induced in TLR4-activated Kupffer cells. TLR4 is expressed by other hepatic cells,including stellate cells and hepatocytes, where TLR-4 exerts actionsrelevant for the pathogenesis and progression of NAFLD towardfibrosis [33]. TLR4-mediated inflammatory responses can also beelicited by DAMPs released by necrotic cells, such as high mobilitygroup box-1 [34].The NOD-like receptors (NLR), which participate in the assem-bly of inflammasomes (multi-protein complexes required forinitiation of inflammatory signals) play a major role in NASHpathogenesis. Activation of the inflammasome is induced byTLRs together with signals linked to cellular damage, e.g., uricacid, reactive oxygen species or adenosine triphosphate, andresults in the secretion of mature IL-1 and IL-18. A role forNLRP3 inflammasome in NAFLD development and progression to NASH has been shown both in humans and in animal mod-els [35]. However, it has also been demonstrated that the lackof NLP3 promotes gut dysbiosis and chronic inflammation [36].Activation of NLRP3 inflammasome has been associated with hep-atocyte pyroptosis, a recently described, inflammasome-mediated,cell death mechanism.Different nuclear receptors have been implicated in the patho-genesis of NASH and development of fibrosis. Importantly, theseproteins may be targeted by drugs already present in the clinicalarena. The receptors on which more information has accumulatedinclude the nuclear farnesoid X receptor (FXR), the peroxisomeproliferator-activated receptor (PPAR)-gamma and the PPAR-alpha[37]. Agonists of these nuclear receptors improve hepatic steato-sis, inflammation and fibrosis, and are being tested in clinical trials(such as discussed at Section 5 in this review).Adipose tissue is recognized as an endocrine organ that secretesa variety of adipokines, which control systemic metabolism andenergy homeostasis. Among these, leptin and adiponectin areinvolved in the pathogenesis of NAFLD and its progression to NASH,leptin being identified as a pro-fibrogenic adipokine, whereasadiponectin decreases inflammation and fibrogenesis [38]. 

2.3.	Microbiota
A huge group of microorganisms, collectively defined as the gutmicrobiota, colonizes the human intestine. It has been estimatedthat human gut harbors at least 100 trillion microbial cells, whichare differently represented along the intestine, reaching thegreatest concentration in the large bowel [39]. Despite a largeinter-individual variation, adult gut microbiota is fairly stable andis dominated by the phyla Firmicutes and Bacteroidetes, followedby Actinobacteria and Verrucomicrobia [40]. Gut microbiota confers the host several physiologic bene-fits, including immune system development, protection frompathogens, and maintenance of intestinal and metabolic homeo-stasis [41]. Quantitative and qualitative changes of gut microbiotacomposition, also called dysbiosis, have been associated withthe development of both intestinal and extra-intestinal diseases,including the MetS. A role of dysbiosis in the development of obe-sity and NAFLD has been demonstrated in both animal and humanstudies. For example, a seminal study showed that the transferof gut microbiota from obese to lean individuals induced in therecipients, the same metabolic alterations of the donors [42]. Gutmicrobiota changes were mainly characterized by an increasedFirmicutes/Bacteroidetes ratio. However, other investigators failedto confirm these findings and suggested that metagenomic-basedfunctional aspects of gut microbiota are likely to be more importantthan phylum specificity [43].Several mechanisms are involved in the development of obe-sity and its associated metabolic complications. In particular, gutmicrobiota can trigger (directly or via the synthesis of end-productsof bacterial metabolism, such as short-chain fatty acids), differ-ent signaling pathways, which eventually lead to an increaseddeposition of peripheral fat [42,44]. Furthermore, several intesti-nal microorganisms can increase the efficiency of caloric extractionfrom the food, thus contributing to the development of obe-sity [45]. Lastly, diet-induced dysbiosis has been associated withincreased gut permeability in both mice [46] and humans [47].This could lead to increased translocation of bacterial productsfrom the intestinal lumen into the portal circulation thereby trigg-ering chronic inflammation. Moreover, within the liver, thesecirculating pathogens can also activate the family of pattern recog-nition receptors (TLRs) and induce pro-inflammatory pathways,which contribute to liver disease development and progression[48–50].

2.4.	Genetics
Genetic factors account for about of half of the variability inintra-hepatic fat content, and fibrosis tends to be co-inherited withsteatosis [26].Recent genome-wide association studies have begun to unveilthe specific common genetic determinants of NAFLD. By far themost important one, due to high frequency and large size effect,is the p.I148 M loss-of-function variant of the Patatin-like phos-pholipase domain containing-3 (PNPLA3) gene. This gene encodesfor a lipase involved in the remodeling of lipid droplets in hepato-cytes and the release of retinol from hepatic stellate cells [51,52].In the presence of endogenous/exogenous noxious stimuli (obe-sity, IR, alcohol and chronic viral hepatitis), carriers of the PNPLA3I148M variant are at increased risk of developing steatohepatitis,cirrhosis and HCC [52].The loss-of-function variant p.E167K variant of the trans-membrane 6 superfamily member 2 (TM6SF2) is more rare, iscarried by about 10% of individuals, and also predisposes toNAFLD and advanced fibrosis/cirrhosis by reducing lipid secre-tion from hepatocytes, while protecting at the same time fromdyslipidemia and cardiovascular disease [53,54]. Other geneticdeterminants of NAFLD include variants of the glucokinase reg-ulatory protein, regulating lipogenesis and the membrane-boundO-acyltransferase domain containing-7, influencing phospholipidmetabolism [55,56].Multiple mutations in genes regulating lipid secretion, such asapolipoprotein B, are also associated with increased risk of severeNAFLD, cirrhosis and HCC, and are responsible for familial cases ofthe disease [57].All these new discoveries are expected to carry out an improve-ment in our ability to gauge the risk in the individual patient,identifying new disease mechanisms and tailored therapeutic tar-gets.

3.	Epidemiology and natural history of NAFLD
3.1. Epidemiology
A recent systematic review and meta-analysis estimated that25% of the world adult population has NAFLD as diagnosed by imag-ing. Although NAFLD was highly prevalent in all continents, thehighest prevalence rates were reported from South America andthe Middle East, whereas the lowest prevalence was reported fromAfrica [58]. In Italy, the prevalence of NAFLD ranges approximatelyfrom 20% [59] to 25% [60–62].Demographic (age, sex and ethnicity) and metabolic modifiers(MetS components) modulate the risk of developing NAFLD. Theprototypic NAFLD patient is a 60-to-85 year-old Hispanic man; incontrast, individuals of European and, in particular, African descentare more spared from NAFLD [63]. Patients with either severeobesity (∼98%) or T2DM (∼70%) are maximally prone to NAFLDdevelopment; NAFLD is equally prevalent in either sex amongpatients with T2DM which, therefore, abrogates the higher preva-lence of the male sex typically observed in non-diabetic NAFLDindividuals [63]. The risk of NAFLD is also maximal (∼85%) amongpatients with combined dyslipidemia and elevated serum amino-transferases [64].The prevalence of NASH ranges from as many as 59.1% amongbiopsied NAFLD patients to 29.9% for North America and 6.7% forAsia, respectively, among patients who are not candidates for liverbiopsy [58].The pooled regional NAFLD incidence estimates for Asia andIsrael were reported to be approximately 52 per 1000 and 28 per1000 person-years, respectively [58]. In Italy, a pioneering studyperformed studyperformed on a cohort of hysterectomized women reported anincidence rate of NAFLD of approximately 2 per 1000 women/year[65].A recent meta-analysis estimated that the pooled mean fibro-sis progression rate per year for patients with biopsy-proven NASHwas 0.09, and approximately 40% of these patients progressed tothe more advanced stages over time [58]. The annual incidence ofHCC in NAFLD patients was 0.44 per 1000 person-years, whereasthe corresponding figure for patients with NASH was 5.3 per1000 person-years [58]. Compared to non-NAFLD control subjects,patients with NAFLD are exposed to an almost two-fold increasedrisk of liver-related mortality [58] and to a substantially increasedrisk of developing fatal and non-fatal CVD events [66].Recent studies have described the specific features of NAFLDepidemiology in lean individuals [67], elderly people [68] and chil-dren [69].

3.2.	Natural history of NAFLD
Hepatic riskNAFLD course has four clinical-pathological entities: steatosis,NASH, advanced fibrosis/cirrhosis, and HCC. Research has focusedon risk factors for each of these steps and factors regulating themigration of patients from each entity to the others [70].
           3.2.1. Steatosis
Normal liver is almost totally devoid of any fat content [71]. Con-versely, most patients with NAFLD will have simple steatosis, (fattychanges affecting >5% of hepatocytes), usually associated with mildchronic inflammation [72,73].Steatosis results from the interaction of multiple factors includ-ing age, sex and lifestyle [70,73]. Body weight mirrors dietary habitsand physical exercise and is a major determinant of NAFLD. Bodyweight changes of as little as 2–3 kg are associated with eitherincreased risk of developing NAFLD or its reversal [74]. Finally,various drugs may contribute to reversing NAFLD [5].
3.2.2.	NASH
Steatosis plus mild inflammatory changes and “ballooning” hep-atocyte degeneration define NASH, which accounts for up to 30% ofNAFLD cases [73].The strongest predictors of NASH are: older age, male sex, andvarious genetic and metabolic risk factors [75–81].Simple steatosis can certainly progress to NASH [82–84]. Thetime to progress to cirrhosis from early, disease would probablytake as long as approximately 57years for steatosis compared to 24years for NASH [3]. The rates of disease progression are slower thanthose observed in HCV infection [85].Glitazones do not significantly reverse hepatocyte ballooning;this finding supports the view that hepatic/systemic IR plays a keyrole in triggering the early phases of NAFLD development ratherthan sustaining its subsequent progression [86].
3.2.3.	Advanced fibrosis/cirrhosis
NASH strongly predicts the development of advanced fibro-sis together with age, body mass index (BMI), sex, genetic andhormonal/metabolic factors [87–94]. Fibrosis, in its turn, stronglypredicts liver-related mortality in NAFLD [95]. Statins seem also toexert some beneficial effect on liver fibrosis progression in patientswith and without T2DM [96,97].NASH-cirrhosis histologically exhibits advanced fibrosis andnodular changes; however, fatty changes may typically disappearover time[98].Obesity, T2DM and steatosis, together with the presence ofcarotid atherosclerotic plaques and increased intima-media thick-ness, are strongly associated with advanced fibrosis/cirrhosis[99–101]. In particular, the coexistence of T2DM and steatosis strongly predicts the development of clinically significant hepaticfibrosis [100].
3.2.4.	HCC
Compared to other etiologies of HCC, NAFLD-HCC is associatedwith a lower male/female ratio and may occur in non-cirrhotic liv-ers [102–104]. NAFLD-HCC is often diagnosed late as a result ofits escaping surveillance protocols, which translates into curtailedchances for radical treatment and accounts for a worse progno-sis compared with HCC caused by viral hepatitis [104–106]. ThePNPLA3 I148M polymorphism, age, BMI, T2DM, dietary habits anddrugs may bi-directionally modulate the risk of developing NAFLD-HCC [92,107–113] and T2DM aggravates HCC outcome [114].
3.3.	Natural history of NAFLD
Cardiovascular, arrhythmic anddiabetes risksCardiovascular disease (CVD) is the leading cause of mortal-ity in patients with NAFLD [95,115–117]. A recent systematicreview and meta-analysis showed that patients with NAFLD hada higher risk of fatal and non-fatal CVD events than those with-out NAFLD [66]. Patients with more ‘severe’ NAFLD were also morelikely to develop fatal and non-fatal CVD events [66]. Althoughthe results of this updated meta-analysis provide robust evidenceof the association between NAFLD (and NAFLD severity) and riskof major CVD events, it is important to highlight that causalityremains to be further proven in high-quality intervention studies.Given that CVD complications frequently dictate the outcome ofNAFLD, a screening of the cardiovascular system is mandatory inall patients with NAFLD, at least by detailed risk factor assessment[11].NAFLD is also linked with subclinical myocardial remodelingand dysfunction (i.e., functional and structural cardiomyopathy),valvular heart diseases (i.e., aortic-valve sclerosis or mitral annuluscalcification), and increased prevalence and incidence of perma-nent atrial fibrillation [118–124]. Moreover, NAFLD is strongly andindependently associated with heart rate-corrected QT intervalprolongation [125,126] and an increased prevalence of ventriculararrhythmias on 24-h ECG-Holter monitoring [127]. Finally, prelim-inary evidence also suggests that NAFLD is associated with higher1-year re-hospitalization rates in patients hospitalized for acuteheart failure [128].For many years, NAFLD has been considered as the simple“hepatic manifestation of the MetS” [63,129]. However, a large num-ber of retrospective and prospective observational studies haverecently demonstrated that NAFLD is an early predictor of and adeterminant for the development of new-onset T2DM and MetS[4,130]. A recent systematic review and meta-analysis confirmedthat NAFLD (as diagnosed either by abnormal serum liver enzymesor by ultrasonography) is indeed associated with almost two-foldincreased incidence rates of both T2DM and MetS over a median5-year follow-up period [7]. Consistently, recent observationalstudies have shown that there is a strong and independent asso-ciation between improvement of NAFLD and decreased incidenceof T2DM [131,132]. Future controlled intervention trials are, there-fore, needed to determine whether treating NAFLD leads to T2DMrisk reduction.
3.4.	Natural history of NAFLD
Cancer riskIndirect evidence for an association of NAFLD with cancer inci-dence and mortality came from large epidemiological studies,which have clearly demonstrated that obesity and T2DM contributeto increased incidence and mortality from several cancer types,including liver and colo-rectal cancers [133–135]. Consistently, lon-gitudinal studies showed that NAFLD was associated with increasedburden of hepatic and extra-hepatic cancers [136] and malignancywas a leading cause of mortality in patients with NAFLD, rankingsecond after CVD mortality [137] and accounting for up to one thirdof deaths in patients with NAFLD and T2DM [138].Primary liver cancer is deemed to be causally associated withNAFLD. HCC incidence is steadily increasing over years in paral-lel with the burst of “diabesity”. NAFLD is becoming a major causeof HCC and the second most common cause of HCC in patientslisted for liver transplantation [106,139]. Worryingly, the wholehistological spectrum of NAFLD can lead to HCC and as manyas 50% of NAFLD-related HCC occur in patients without cirrho-sis and are often detected late [104]. Cumulative HCC incidenceor mortality rates seem to be lower in NASH-cirrhosis than incirrhosis due to other etiologies; however, it is not possible toclearly gauge the actual HCC risk in the whole NAFLD popula-tion [140–142]. Apart from advanced fibrosis/cirrhosis, data onlypoint to male sex, older age, alcohol abuse and MetS compo-nents as established clinical risk factors for HCC development inNAFLD [108,143,144]. For these reasons, except for patients withNASH-cirrhosis, specific surveillance/screening strategies cannotbe currently recommended in NAFLD patients. Mounting evidencealso suggests that MetS and NAFLD are involved in the developmentof other types of primary benign and malignant liver tumors, i.e.hepatocellular adenoma [145,146] and intra-hepatic cholangiocar-cinoma [147–150]. Of note, the interplay between NAFLD and HCCseems to be more complex than the classic linear equation fibrosis-cirrhosis-dysplasia, and probably hepatocellular adenoma plays arole in this process [103,151,152].Emerging evidence also suggests a link between NAFLD andsome extra-hepatic cancers, typically those closely associated with“diabesity” [153]. In particular, colorectal adenoma and cancerhave been associated with NAFLD by retrospective studies fromAsia, USA and Europe [154–157]. There are also isolated reportsof an increased risk of other gastrointestinal (esophagus, stom-ach and pancreas) and extra-gastrointestinal malignancies (kidney,prostate, lung and breast) [136,153,158–160]. However, all thesedata are preliminary, and their validity remains to be evaluatedprospectively before specific surveillance/screening strategies maybe issued.

4.	Diagnosis and clinical approach to NAFLD
4.1.	Diagnosis
Given that approximately one third of the adult Europe andUSA populations have NAFLD and that invasive diagnostic tech-niques are not applicable in this impressive number of individuals,non-invasive biomarkers of steatosis and fibrosis are necessary. Asshown in Fig. 2, the recently published European clinical practiceguidelines for the management of NAFLD have proposed a diagnos-tic flow-chart to assess and monitor disease severity in the presenceof suspected NAFLD and metabolic risk factors [11]. The diagnosis of NAFLD should rely on the following criteria:(i) hepatic steatosis on either imaging or histology, (ii) no exces-sive alcohol consumption (a threshold of 20 g/day for women and30 g/day for men is conventionally adopted), and (iii) no competingcauses of hepatic steatosis [11]. Liver biopsy remains the reference standard for diagnosing NASHand staging fibrosis in patients with NAFLD. However, this proce-dure is invasive, potentially risky, patient unfriendly and subject tosampling error; therefore, liver biopsy is not suitable for diagnosisin large cohorts of individuals or for patient monitoring [11].Imaging techniques. The gold standard to diagnose hepaticsteatosis is the magnetic resonance imaging (MRI) or spectroscopy(MRS) that can detect amount of fat as low as 1% [11]. However,the cost of MRI limits its routine clinical use. Ultrasonography remains the recommended first-line imaging modality in clinicalpractice, but its accuracy is much lower than that of MRI/MRS andits cost is also lower than that of MRI. Recently, with the devel-opment of new imaging sequences for MRI, time of screening isdecreased (approximately 10–15 min/session) and thus the costcan become more affordable [161,162]. Other imaging techniques,e.g. ultrasonography-based transient elastography (Fibroscan), 2Dacoustic radiation force impulse imaging or MR-elastography, canalso be used to diagnose liver fibrosis [11]. The main limitation ofultrasonography-based transient elastography in clinical practiceis its failure to obtain reliable liver stiffness measurements (∼20%of cases), mainly in obese patients, which diminishes its applicationin NAFLD.Serum biomarkers. Hepatic steatosis is often associated withmild-to-moderate elevations of serum aminotransferase andgamma-glutamyl transferase (GGT) levels, but, at best, liverenzymes only identify people who are at increased risk of NAFLDand who require further diagnostic tests. However, serum liverenzyme levels are inaccurate indicators for and, therefore, shouldnot be used alone in clinical practice [11]. Among the best scoresfor steatosis there are the fatty liver index (FLI) [163], the NAFLDliver fat score [164] and the SteatoTest [165]. The first two scorescan be easily calculated using serum triglycerides, GGT, insulin andaminotransferases, BMI, waist circumference and presence of MetSor T2DM [166]. The SteatoTest is a commercial kit.A common clinical concern in patients with NAFLD is whetherthey have simple steatosis or NASH and, more importantly, whatthe stage of hepatic fibrosis is and whether the level of fibrosis(which dictates clinical outcome) has increased over time. Thereare various hepatic fibrosis non-invasive biomarkers: the NAFLDfibrosis score [167], the FIB-4 [168], the FibroTest, the Fibrom-eter, and the Enhanced Liver Fibrosis (ELF) score [165,169]. Thefirst two scores can be calculated using platelet count, albumin,and aminotransferases. The FibroTest, Fibrometer and ELF scoresare commercial tests. Although non-invasive methods require fur-ther validation, the various tests could be useful for selecting thosepatients with NAFLD who will require a liver biopsy. However, forthe diagnosis of NASH biochemical tests or imaging techniquescannot distinguish NASH from simple steatosis and liver biopsyremains the reference standard [11].
4.2.	Clinical approach 
CVD complications are common in NAFLD patients and the riskof CVD and poor CVD outcomes is particularly increased in those NAFLD patients with severe liver damage [95,117], suggesting thatNAFLD exerts a pro-atherogenic effect via a pro-inflammatory andpro-fibrogenic milieu that characterizes severe disease [170].On these grounds, a careful assessment of cardiovascular risk(CVR) in all patients with NAFLD is warranted. It should include theassessment of traditional CVR factors and also indices of severity ofliver disease, (serum sodium and albumin, the Model for end-stageliver disease (MELD) score and the NAFLD fibrosis score [171]).Whether PNPLA3 [172] and TM6SF2 [54] gene variants, which areassociated with CVD alterations in NAFLD, may help to stratify theCVR needs further investigation.Overall, both hepatic and extra-hepatic risk factors should beevaluated in all patients with NAFLD. Namely, besides the non-invasive assessment of liver damage (as described above), a carefulsearch for cardio-metabolic comorbidities should also include theevaluation of family history for CVD/T2DM, the assessment of BMIand waist circumference, the measurement of plasma lipid val-ues, estimated glomerular filtration rate and albuminuria and, inselected cases, the genetic assessment for storage disorders, suchas the lysosomal acid lipase deficiency [116,173]. In nondiabeticpatients, screening for T2DM by measuring fasting or random bloodglucose or hemoglobin A1c levels is also mandatory. Similarly,repeated assessment of arterial pressure should be recommendedto non-hypertensive patients. Finally, CVR assessment should relynot only on the available CVR scoring systems, such as the Fra-mingham or “Progetto cuore” risk charts, but also on the assessmentof the severity of liver disease [171]. In patients at high CVR orwith established T2DM, referral to cardiologists should also beconsidered and further diagnostic tests performed whenever indi-cated. In nondiabetic patients at low CVR, re-assessment every2–3 years may be suggested based on clinical judgment alone.Patients with advanced fibrosis/cirrhosis should enter appropriatefollow-up schedules aimed at an early diagnosis of HCC and portalhypertension. However, a generalized HCC screening policy cannotbe recommended in all non-cirrhotic NAFLD patients at present,although certain NAFLD individuals are at an increased risk.Finally, in patients with dyslipidemia, hypertension or T2DM,the careful control of these cardiometabolic disorders will not onlyreduce the NAFLD-associated metabolic and CVR, but also slow liverdisease progression. To achieve this goal statins, insulin-sensitizers,incretin mimetics and ACE-inhibitors/sartans, if necessary, cansafely be used.
5.	Treatment of NAFLD/NASH
5.1. Nutritional aspects and lifestyle changes
All the recommendations from the most important scientific societies indicate that body weight reduction obtained through lifestyle changes is the most effective treatment for NAFLD. A large body of evidence indicates that unhealthy life-style is a relevant risk factor for NAFLD/NASH [17,174]. Accordingly, lifestyle changes focusing on weight loss, physical activity and healthy diet represent the best therapeutic approach [175].A body weight reduction of 7–10% obtained with energy restric-tion and/or regular physical activity is associated with histological improvement/resolution of steatosis and inflammation and regression of fibrosis [176,177].Energy restriction should be obtained with a low-calorie (about1200–1600 kcal/day) low-fat low-carbohydrate diet [178]. The diet composition in NAFLD should consist of <30% fat, notably with nomore than 10% of saturated fatty acid, and relatively low in carbohydrates, ∼50% of total kcal, notably by reducing high-sugar food[179].As for physical activity, both aerobic activities(150–200 min/week of moderate intensity aerobic exercise in about four sessions, i.e. brisk walking and/or stationery cycling)and resistance training effectively reduce hepatic fat content. Training should be tailored based on patients’ preferences and maintained long-term [177,180,181].Changes of diet composition, especially for non-obese patients, are a realistic and feasible approach even if based on less consistent evidence [182]. The gold standard option is a fiber-rich diet relatively low in carbohydrates (complex ones should be preferred)and fat content, with the avoidance of fructose [179], a moderateuse of coffee and adherence to a Mediterranean dietary pattern[183,184]. Indeed, among all the proposed diets, the Mediterranean diet appears as the most effective dietary option for inducing aweight loss together with beneficial effects on all cardio-metabolic risk factors associated with NAFLD.
5.2. New drugs for NASH 
Drug therapy should be reserved for NASH patients who are atmaximal risk for disease progression. To date, there are very fewhigh-quality, randomized, blinded, adequately powered, controlledstudies of sufficient duration and with adequate histological out-comes. As a fact, currently there are no approved available drugsfor the treatment of NASH. Moreover, drug treatment of NASH hasbeen focused toward reducing steatosis, necro-inflammation andfibrosis.Given that NASH is closely related to T2DM, hypoglycemicdrugs have been largely evaluated. In patients with T2DM, incretinmimetics, which act by agonizing glucagon-like peptide 1 (GLP-1) receptor, have proven effective in reducing hepatic/systemic IR,serum liver enzymes and liver fat content. The LEAN trial performedon 52 obese patients showed that liraglutide was able to resolvehistologic features of NASH in 39% of the treated patients [185].These responders also registered a mean weight loss of 2.1 kg rais-ing uncertainty as to whether the beneficial hepatic effect was dueto liraglutide per se or combined with weight loss. Further long-term studies with liraglutide are needed to confirm its efficacy inpatients with NASH.Other insulin-sensitizers, such as PPAR- _ agonists have beenevaluated in NASH [186]. The best level of evidence is available forpioglitazone in biopsy-proven NASH patients [187]. PPARs modula-tion results in transcriptional regulation of several genes involvedin metabolic pathways [188] and the modulation of a dual PPAR- _/ _ agonist through elafibranor is effective in improving plasmalipid profile, and hepatic/systemic IR [189]. In the phase IIb GOLDENtrial, elafibranor was tested with a primary histological end-point(NASH resolution without fibrosis worsening), which was achievedin 23% and 21% of patients treated with either 80 mg/day or120 mg/day, respectively [190]. Post-hoc analysis showed a clearbenefit in patients with more severe disease, prompting a phase IIItrial.Another nuclear receptor to be targeted to obtain reduced IR andliver injury, is FXR, an intracellular bile acids receptor [191] capableof inhibiting bile acids synthesis, reducing de novo lipogenesis andsteatosis by improving IR. In the FLINT trial, treatment with obeti-cholic acid, a potent FXR activator, achieved a primary end-pointof improving the necro-inflammation without worsening of fibro-sis in 46% of the treated patients. Moreover, compared to placebo,the NASH resolution was obtained in 22% of treated patients [192].However, efficacy and long-term safety (e.g., pruritus and increased LDL-cholesterol levels) associated with the use of this drug need tobe addressed. And a phase III study is now ongoing to this end.Another therapeutic option for NAFLD may be to decrease oxida-tive stress by administration of an antioxidant, such as vitamin E.In the PIVENS trial [187], in 247 nondiabetic NASH adults, vita-min E treatment (800 U/day for 96 weeks), was associated withsignificant improvements in serum liver enzymes and NASH histo-logical features (steatosis, inflammation and ballooning) comparedto placebo. However, before vitamin E can be recommended for thetreatment of NAFLD, further studies are required to support efficacyand safety of this fat-soluble vitamin.At today, only elafibranor and obeticholic acid are recruitingfor phase III trials; results are expected in 2020. Moreover, severalother phase II trials are in progress to evaluate the effect of newerdrugs on different pathogenic pathways involved in NASH. Table 1recapitulates ongoing clinical trials for NASH in adult subjects.Promising results are expected for novel drugs, which improvemetabolic disturbances such as Aramchol (phase II trial), a conju-gate of cholic and arachidic acid, which partially reduces the activityof stearoyl-CoA desaturase and de novo lipogenesis [193,194].Emricasan [195], an oral pan-caspase inhibitor acting on TNF-alpha driven inflammation, seems to be effective in reducing liverdamage by modulating apoptosis. Cenicriviroc [196], an oral antag-onist of chemokine CCR2/CCR5, has recently closed the phase IItrial and results are expected. The possibility of reverting fibro-sis and cirrhosis has also been explored by using simtuzumab,a monoclonal antibody against lysyloxidase-like-2, which is anextra-cellular amine oxidase involved in the post-translationalmodification of collagens and elastin in the extracellular matrix[197].
6.	Conclusions and perspectives
A great deal of new knowledge in the physiopathology of NAFLDhas been accumulating over the last decade, revealing the complex-ity of the mechanisms involved in the development and progressionof this condition. The most recent guidelines/expert opinions forNAFLD management prompt a new “systems medicine” approachto the interplays between brain and nervous system, endocrinesystem, digestive system (gut, liver and microbiota) and immunesystem [11,198]. New concepts for patient stratification are neededto identify different clinical prototypes within the indistinct phe-notype of the MetS [11,198].The emerging and rapidly growing field of the molecularimaging will likely be providing an extraordinary new opportunityfor non-invasive studies of in vivo physiopathology of NAFLDovercoming the inherent limitations of liver biopsy [161,199,200].Such limitations have so far hampered the progress of the knowl-edge in key fields such as the impact and role of autophagy inthe physiopathology of NAFLD [201]. Studies combining the newimaging techniques with liver and blood metabolomics and theanalysis of the interplay between specific genes and the epigeneticfactors conditioning their expression, will pave an attractive newway to targeting the dynamics of pathogenic processes involved inNAFLD and NASH. The results of these ongoing studies will identifynovel risk factors, new diagnostic and prognostic biomarkersand therapy targets for a better prevention, outcome predictionand personalized treatment of NAFLD/NASH. In the meantime,to halt/reduce the tide of NAFLD, reference should be made tostandard principles of good clinical practice for the managementof this condition [11,15,202,203], which is expected to impact onthe future global burden of disease worldwide.
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